Order zithromax

The Clinical Trials order zithromax for Medical Devices and Drugs Relating to buy antibiotics Regulations (Regulations) were published on March 2, 2022. They came into effect on February 27, 2022, following the repeal of Interim Order No. 2 respecting clinical trials order zithromax for medical devices and drugs relating to buy antibiotics (IO No. 2).

IO No. 2 was order zithromax made on May 3, 2021. The flexibilities under IO No. 2 will continue under the Regulations.

This will ensure order zithromax 2 things. sponsors may continue conducting clinical trials authorized under the interim order all authorizations, suspensions and exemptions for clinical trials issued under the interim order will remain in effect On this page Overview IO No. 2 provides a more flexible authorization and implementation pathway for the clinical trials of drugs and medical devices used to diagnose, treat, mitigate or prevent buy antibiotics in people. The provisions of IO order zithromax No.

2 are set to expire on May 3, 2022. They will be replaced by the Regulations, which came into force on February 27, 2022. The Regulations maintain the flexibilities order zithromax set out by the interim order until the framework established through the Clinical Trials Modernization Initiative is in place. By maintaining the pathway set out by the IO, the Regulations will continue to facilitate the authorization and implementation of buy antibiotics-related clinical trials.

In addition to reducing administrative burden, they will continue to uphold the health and safety requirements for trial participants and ensure the validity of trial data. Under the Regulations, all clinical trials applications (and order zithromax amendments) for buy antibiotics-related drugs and medical devices will continue to be reviewed within 14 days. Research ethics boards are also prioritizing reviews and approvals for buy antibiotics clinical trials. Transition plan for clinical trial authorizations A flexible order zithromax pathway Under the Regulations, all authorizations and suspensions for clinical trials issued under IO No.

2, including any terms and conditions, will remain in effect. Any applications and amendments made under IO No. 2 that are outstanding when it's repealed will be considered order zithromax as applications and amendments made under the Regulations. In addition, we have made minor changes to clarify the following.

the classification framework for medical devices in the Medical Devices Regulations applies to the Regulations the type of information or material that, if changed significantly, would require an amendment to an authorization for clinical trials involving buy antibiotics medical devices We have also improved the wording of the provisions related to amendments to authorizations (sections 8 and 24 of the Regulations). The improvements order zithromax align with good drafting practices. They also more accurately describe the obligations of authorization holders in these situations. Records retention The Regulations include amendments to the records retention periods that were temporarily required under IO No.

2. Under the Regulations, records for all clinical trials of buy antibiotics drugs must be kept for 15 years. For clinical trials of medical devices, clinical trial records must be kept for the entire authorization period. Distribution records for medical devices must be kept for whichever is longer.

the projected useful life of the device or 2 years after the date the authorization holder first took possession, care or control of the device in Canada At the same time, we have amended the Food and Drugs Regulations and the Natural Health Products Regulations to reduce the records retention period from 25 years to 15 years for clinical trials of drugs and natural health products. Consequential amendment to the Certificate of Supplementary Protection Regulations The Regulations include a consequential amendment to the Certificate of Supplementary Protection Regulations (CSPR) to exclude authorizations under section 21 and amendments under subsection 24(2) of the Regulations from the definition of 'authorization for sale' in the CSPR, just as clinical trial authorizations and amendments under sections C.05.006 and C.05.008 of the FDR and sections 67 and 71 of the NHPR are currently excluded. We also made a minor amendment to ensure consistency between the English and French and to avoid repetition. For more information about this notice, please contact Health Canada's Therapeutic Products Directorate at policy_bureau_enquiries@hc-sc.gc.ca.

Zithromax online no prescription

Notice: Undefined variable: FsFrom in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/api.php on line 116
Notice: Undefined variable: FsFrom in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/api.php on line 117
Notice: Undefined variable: FsFrom in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/api.php on line 180
Notice: Undefined variable: FsTo in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/api.php on line 180
Warning: [obfuscated]() expects parameter 1 to be array, null given in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/text.php on line 0
Warning: [obfuscated](): Invalid arguments passed in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/text.php on line 0
Warning: [obfuscated](): Invalid arguments passed in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/text.php on line 0
Notice: Undefined variable: FsFrom in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/api.php on line 180
Notice: Undefined variable: FsTo in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/api.php on line 180
Warning: [obfuscated]() expects parameter 1 to be array, null given in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/text.php on line 0
Warning: [obfuscated](): Invalid arguments passed in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/text.php on line 0
Warning: [obfuscated](): Invalid arguments passed in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/text.php on line 0

How should I take Zithromax?

Swallow tablets whole with a full glass of water. Azithromycin tablets can be taken with or without food. Take your doses at regular intervals. Do not take your medicine more often than directed. Finish the full course prescribed by your prescriber or health care professional even if you think your condition is better. Do not stop taking except on your prescriber''s advice. Contact your pediatrician or health care professional regarding the use of Zithromax in children. Special care may be needed. Overdosage: If you think you have taken too much of Zithromax contact a poison control center or emergency room at once. NOTE: Zithromax is only for you. Do not share Zithromax with others.

Contraindications for zithromax

A study recently completed at the University of Helsinki revealed that the fungal microbiota in the gut is contraindications for zithromax more abundant and diverse in children treated with antibiotics compared with the control group even six weeks following the start of the antibiotic course. In light of the findings, a reduction in the number of gut bacteria as a result of antibiotic therapy reduces competition for space and leaves more room for fungi to multiply."The results of our research strongly contraindications for zithromax indicate that bacteria in the gut regulate the fungal microbiota and keep it under control. When bacteria are disrupted by antibiotics, fungi, Candida in particular, have the chance to reproduce," says PhD student Rebecka Ventin-Holmberg from the University of Helsinki.A new key finding in the study was that the changes in the fungal gut microbiota, together with the bacterial microbiota, be part of the cause of the long-term adverse effects of antibiotics on human health.Long-term changes in infant gut microbiotaAntibiotics are the most commonly prescribed drugs for infants. They cause changes in the gut microbiota at its most important developmental contraindications for zithromax stage. These changes have also been found to be more long-term compared with those of adults."Antibiotics can have adverse effects on both the bacterial and the fungal microbiota, which can result in, for example, antibiotic-associated diarrhea," Ventin-Holmberg says.

advertisement "In addition, antibiotics increase the risk of developing chronic inflammatory diseases, such as inflammatory bowel disease (IBD), and they have been found also to contraindications for zithromax have a link to overweight," she adds.These long-term effects are thought to be caused, at least partly, by an imbalance in the gut microbiota.In the gut, everything is connectedThe recently published study involved infants with a respiratory syncytial zithromax (RSV) who had never previously received antibiotics. While some of the children were given antibiotics due to complications, others received no antibiotic therapy throughout the study."Investigating the effects of antibiotics is important for the development of techniques that can be used to avoid chronic inflammatory diseases and other disruptions to the gut microbiota in the future," Ventin-Holmberg emphasises.While the effect of antibiotics on bacterial microbiota contraindications for zithromax has been previously investigated, studies on fungal microbiota have been scarce. The findings of this study indicate that fungal microbiota may also have a role in the long-term effects of imbalance in the gut microbiota."Consequently, future research should focus on all micro-organisms in the gut together to better understand their interconnections and to obtain a better overview of the microbiome as a whole," Ventin-Holmberg notes. Story Source contraindications for zithromax. Materials provided by University of Helsinki.

Note. Content may be edited for style and length.Understanding the molecular mechanisms that specify and maintain the identities of more than 200 cell types of the human body is arguably one of the most fundamental problems in molecular and cellular biology, with critical implications for the treatment of human diseases. Central to the cell fate decision process are stem cells residing within each tissue of the body.When stem cells divide, they have the remarkable ability to choose to self-renew -- that is, make a copy of themselves -- or mature into defined lineages. How a specific lineage identity is maintained every time a stem cell divides can now be better understood thanks to the work of a team led by biochemists at the University of California, Riverside.The study led by Sihem Cheloufi and Jernej Murn, both assistant professors in the Department of Biochemistry, shows how a protein complex, called chromatin assembly factor-1, or CAF-1, controls genome organization to maintain lineage fidelity. The report appears today in Nature Communications.Each time a cell divides, it has to create a replica of its genome -- not only its DNA sequence but also how the DNA is packaged with proteins into chromatin.

Chromatin is organized into genomic sites that are either open and easily accessible or more densely packed and less accessible (or closed)."Identities of different cells rely heavily on the genome sites that are more open because only genes located in those regions can potentially become expressed and turned into proteins," Cheloufi explained.She added that to maintain cell identity during cell division, the locations of open and closed chromatin, or "chromatin organization," must be faithfully passed onto the new replica of the genome, a task largely entrusted to CAF-1. advertisement "To help CAF-1 secure correct chromatin organization during cell division, a host of transcription factors are attracted to open regions in a DNA sequence-specific manner to serve as bookmarks and recruit transcription machinery to correct lineage-specific genes, ensuring their expression," she said. "We wondered about the extent to which CAF-1 is required to maintain cell-specific chromatin organization during cell division."The authors took as a study paradigm immature blood cells that can either self-renew or turn into neutrophils, which are non-dividing cells that present our body's first line of defense against pathogens. Intriguingly, they found CAF-1 to be essential not only for maintaining the self-renewal of these immature blood cells, but for preserving their lineage identity. Even a moderate reduction of CAF-1 levels caused the cells to forget their identity and adopt a mixed lineage stage."Neutrophil stem cells missing CAF-1 become more plastic, co-expressing genes from different lineages, including those of red blood cells and platelets," Cheloufi said.

"This is very intriguing from a developmental biology perspective."At the molecular level, the team found that CAF-1 normally keeps specific genomic sites compacted and inaccessible to specific transcription factors, especially one called ELF1."By looking at chromatin organization, we found a whole slew of genomic sites that are aberrantly open and attract ELF1 as a result of CAF-1 loss," Murn said. "Our study further points to a key role of ELF1 in defining the fate of several blood cell lineages."The UCR researchers used immature blood cells derived from mouse bone marrow and engineered for growth in tissue culture. They validated their findings in vivo using a mouse model in collaboration with Andrew Volk, a hematology expert at the Cincinnati Children's Hospital Medical Center and a co-corresponding author on the study. advertisement Next, Cheloufi and her colleagues would like to understand the mechanism by which CAF-1 preserves the chromatin state at specific sites and whether this process works differently across different cell types."Like a city, the genome has its landscape with specific landmarks," Cheloufi said. "It would be interesting to know how precisely CAF-1 and other molecules sustain the genome's 'skyline.' Solving this problem could also help us understand how the fate of cells could be manipulated in a predictive manner.

Given the fundamental role of CAF-1 in packaging the genome during DNA replication, we expect it to act as a general gatekeeper of cellular identity. This would in principle apply to all dividing cells across numerous tissues, such as cells of the intestine, skin, bone marrow, and even the brain."Cheloufi, Murn, and Volk were joined in the study by several UCR students, including first author Reuben Franklin, Yiming Guo, Shiyang He, Meijuan Chen, Carmen Chiem. As well as numerous collaborators among them Russell Rockne at the City of Hope, Maria Ninova at UCR, and Dr. David Sykes and Ruslan Sadreyev at the Massachusetts General Hospital.The study was supported by the Department of Defense, National Institutes of Health, City of Hope/UCR biomedical research initiative, and UC cancer research coordinating committee.The title of the research paper is "Regulation of Chromatin Accessibility by the Histone Chaperone CAF-1 Sustains Lineage Fidelity.".

A study recently completed at the University of Helsinki revealed that the fungal microbiota in the gut is more abundant and diverse i thought about this in children treated with antibiotics compared with the control group order zithromax even six weeks following the start of the antibiotic course. In light of the findings, a reduction in the number of gut bacteria as a result of antibiotic therapy reduces competition for space and leaves more room for fungi to order zithromax multiply."The results of our research strongly indicate that bacteria in the gut regulate the fungal microbiota and keep it under control. When bacteria are disrupted by antibiotics, fungi, Candida in particular, have the chance to reproduce," says PhD student Rebecka Ventin-Holmberg from the University of Helsinki.A new key finding in the study was that the changes in the fungal gut microbiota, together with the bacterial microbiota, be part of the cause of the long-term adverse effects of antibiotics on human health.Long-term changes in infant gut microbiotaAntibiotics are the most commonly prescribed drugs for infants. They cause changes in the gut microbiota at its order zithromax most important developmental stage. These changes have also been found to be more long-term compared with those of adults."Antibiotics can have adverse effects on both the bacterial and the fungal microbiota, which can result in, for example, antibiotic-associated diarrhea," Ventin-Holmberg says.

advertisement "In addition, antibiotics increase the risk of developing chronic inflammatory diseases, such as inflammatory bowel disease (IBD), and they have order zithromax been found also to have a link to overweight," she adds.These long-term effects are thought to be caused, at least partly, by an imbalance in the gut microbiota.In the gut, everything is connectedThe recently published study involved infants with a respiratory syncytial zithromax (RSV) who had never previously received antibiotics. While some of the children were given antibiotics due to complications, others received no antibiotic therapy throughout the study."Investigating the effects of antibiotics is important for the development of techniques that can be used to avoid chronic inflammatory diseases and other disruptions to the gut microbiota in the future," Ventin-Holmberg emphasises.While the order zithromax effect of antibiotics on bacterial microbiota has been previously investigated, studies on fungal microbiota have been scarce. The findings of this study indicate that fungal microbiota may also have a role in the long-term effects of imbalance in the gut microbiota."Consequently, future research should focus on all micro-organisms in the gut together to better understand their interconnections and to obtain a better overview of the microbiome as a whole," Ventin-Holmberg notes. Story Source order zithromax. Materials provided by University of Helsinki.

Note. Content may be edited for style and length.Understanding the molecular mechanisms that specify and maintain the identities of more than 200 cell types of the human body is arguably one of the most fundamental problems in molecular and cellular biology, with critical implications for the treatment of human diseases. Central to the cell fate decision process are stem cells residing within each tissue of the body.When stem cells divide, they have the remarkable ability to choose to self-renew -- that is, make a copy of themselves -- or mature into defined lineages. How a specific lineage identity is maintained every time a stem cell divides can now be better understood thanks to the work of a team led by biochemists at the University of California, Riverside.The study led by Sihem Cheloufi and Jernej Murn, both assistant professors in the Department of Biochemistry, shows how a protein complex, called chromatin assembly factor-1, or CAF-1, controls genome organization to maintain lineage fidelity. The report appears today in her response Nature Communications.Each time a cell divides, it has to create a replica of its genome -- not only its DNA sequence but also how the DNA is packaged with proteins into chromatin.

Chromatin is organized into genomic sites that are either open and easily accessible or more densely packed and less accessible (or closed)."Identities of different cells rely heavily on the genome sites that are more open because only genes located in those regions can potentially become expressed and turned into proteins," Cheloufi explained.She added that to maintain cell identity during cell division, the locations of open and closed chromatin, or "chromatin organization," must be faithfully passed onto the new replica of the genome, a task largely entrusted to CAF-1. advertisement "To help CAF-1 secure correct chromatin organization during cell division, a host of transcription factors are attracted to open regions in a DNA sequence-specific manner to serve as bookmarks and recruit transcription machinery to correct lineage-specific genes, ensuring their expression," she said. "We wondered about the extent to which CAF-1 is required to maintain cell-specific chromatin organization during cell division."The authors took as a study paradigm immature blood cells that can either self-renew or turn into neutrophils, which are non-dividing cells that present our body's first line of defense against pathogens. Intriguingly, they found CAF-1 to be essential not only for maintaining the self-renewal of these immature blood cells, but for preserving their lineage identity. Even a moderate reduction of CAF-1 levels caused the cells to forget their identity and adopt a mixed lineage stage."Neutrophil stem cells missing CAF-1 become more plastic, co-expressing genes from different lineages, including those of red blood cells and platelets," Cheloufi said.

"This is very intriguing from a developmental biology perspective."At the molecular level, the team found that CAF-1 normally keeps specific genomic sites compacted and inaccessible to specific transcription factors, especially one called ELF1."By looking at chromatin organization, we found a whole slew of genomic sites that are aberrantly open and attract ELF1 as a result of CAF-1 loss," Murn said. "Our study further points to a key role of ELF1 in defining the fate of several blood cell lineages."The UCR researchers used immature blood cells derived from mouse bone marrow and engineered for growth in tissue culture. They validated their findings in vivo using a mouse model in collaboration with Andrew Volk, a hematology expert at the Cincinnati Children's Hospital Medical Center and a co-corresponding author on the study. advertisement Next, Cheloufi and her colleagues would like to understand the mechanism by which CAF-1 preserves the chromatin state at specific sites and whether this process works differently across different cell types."Like a city, the genome has its landscape with specific landmarks," Cheloufi said. "It would be interesting to know how precisely CAF-1 and other molecules sustain the genome's 'skyline.' Solving this problem could also help us understand how the fate of cells could be manipulated in a predictive manner.

Given the fundamental role of CAF-1 in packaging the genome during DNA replication, we expect it to act as a general gatekeeper of cellular identity. This would in principle apply to all dividing cells across numerous tissues, such as cells of the intestine, skin, bone marrow, and even the brain."Cheloufi, Murn, and Volk were joined in the study by several UCR students, including first author Reuben Franklin, Yiming Guo, Shiyang He, Meijuan Chen, Carmen Chiem. As well as numerous collaborators among them Russell Rockne at the City of Hope, Maria Ninova at UCR, and Dr. David Sykes and Ruslan Sadreyev at the Massachusetts General Hospital.The study was supported by the Department of Defense, National Institutes of Health, City of Hope/UCR biomedical research initiative, and UC cancer research coordinating committee.The title of the research paper is "Regulation of Chromatin Accessibility by the Histone Chaperone CAF-1 Sustains Lineage Fidelity.".

Zithromax 500mg dosage

Notice: Undefined variable: FsFrom in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/api.php on line 116
Notice: Undefined variable: FsFrom in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/api.php on line 117
Notice: Undefined variable: FsFrom in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/api.php on line 180
Notice: Undefined variable: FsTo in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/api.php on line 180
Warning: [obfuscated]() expects parameter 1 to be array, null given in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/text.php on line 0
Warning: [obfuscated](): Invalid arguments passed in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/text.php on line 0
Warning: [obfuscated](): Invalid arguments passed in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/text.php on line 0
Notice: Undefined variable: FsFrom in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/api.php on line 180
Notice: Undefined variable: FsTo in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/api.php on line 180
Warning: [obfuscated]() expects parameter 1 to be array, null given in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/text.php on line 0
Warning: [obfuscated](): Invalid arguments passed in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/text.php on line 0
Warning: [obfuscated](): Invalid arguments passed in /var/www/adminuser/data/www/xuletext.com/rb/inc/lib/model/text.php on line 0

How much is zithromax at walmart

By Steven how much is zithromax at walmart http://buzz-feed.co.uk/buy-kamagra-oral-jelly-in-canada/ Reinberg HealthDay ReporterHealthDay ReporterFRIDAY, Aug. 12, 2022 (HealthDay News) -- The Inflation Reduction Act is expected to bring out-of-pocket drug costs down for many U.S how much is zithromax at walmart. Seniors, but most of its benefits aren't immediate.Under the law, Medicare will now be allowed to negotiate the cost of some drugs.

That should eventually bring down out-of-pocket costs for seniors with how much is zithromax at walmart Medicare Part D prescription drug plans, according to John Clark, a clinical associate professor at the University of Michigan College of Pharmacy. Previously, Medicare was not allowed to negotiate drug prices.Under the law — which goes to President Joe Biden how much is zithromax at walmart after it clears the U.S. House of Representatives — the number of medications will be phased in, beginning in 2026 with 10 drugs.

Beginning next year, drug companies will be required to pay rebates if drug prices rise faster than inflation, which they often do.Also how much is zithromax at walmart starting next year, treatments will be free for Part D recipients. These savings will not be passed on to seniors with private insurance. In 2024, how much is zithromax at walmart the 5% co-insurance required for Part D catastrophic coverage ends.

This is how much is zithromax at walmart expected to benefit an estimated 3 million Americans.In addition, out-of-pocket drug costs will be capped at $2,000 for Medicare beneficiaries beginning in 2025.The Congressional Budget Office predicts that the reforms will save the government $288 billion over 10 years.Whether this new law will actually benefit patients is yet to be seen, Clark noted in a university news release, but this is the first intervention in drug prices for Americans who pay more than others in the world for the same drugs.A cap on insulin prices for all Americans was not included in the new law, which some see as a win for drug companies, Clark said.More informationThe U.S. Centers for Medicare and Medicaid Services has more about federal health insurance programs.SOURCE. University of Michigan, news release, Aug how much is zithromax at walmart.

By Steven order zithromax Reinberg HealthDay ReporterHealthDay ReporterFRIDAY, Aug http://buzz-feed.co.uk/buy-kamagra-oral-jelly-in-canada/. 12, 2022 (HealthDay News) -- The Inflation Reduction order zithromax Act is expected to bring out-of-pocket drug costs down for many U.S. Seniors, but most of its benefits aren't immediate.Under the law, Medicare will now be allowed to negotiate the cost of some drugs. That should eventually bring down out-of-pocket costs for seniors with Medicare Part D prescription drug plans, order zithromax according to John Clark, a clinical associate professor at the University of Michigan College of Pharmacy.

Previously, Medicare was not allowed to negotiate drug prices.Under the law — which goes to President order zithromax Joe Biden after it clears the U.S. House of Representatives — the number of medications will be phased in, beginning in 2026 with 10 drugs. Beginning next year, drug companies will be required order zithromax to pay rebates if drug prices rise faster than inflation, which they often do.Also starting next year, treatments will be free for Part D recipients. These savings will not be passed on to seniors with private insurance.

In 2024, the 5% co-insurance required order zithromax for Part D catastrophic coverage ends. This is expected to benefit an estimated 3 million Americans.In addition, out-of-pocket drug costs will be capped at $2,000 for Medicare beneficiaries beginning in 2025.The Congressional Budget Office predicts that the reforms will save the government $288 billion over 10 years.Whether this new law will actually benefit patients is yet to be seen, Clark noted in a university news release, but this is the first intervention in drug prices for Americans who pay more than others in the world for the same drugs.A cap on insulin prices for all order zithromax Americans was not included in the new law, which some see as a win for drug companies, Clark said.More informationThe U.S. Centers for Medicare and Medicaid Services has more about federal health insurance programs.SOURCE. University of Michigan, news release, order zithromax Aug.

Bactrim and zithromax

("Health Catalyst," buy zithromax online cheap Nasdaq bactrim and zithromax. HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended March 31, 2022. €œIn the first quarter of 2022, I am pleased to share that we began the year by achieving strong performance across our business, including exceeding the mid-point of our quarterly guidance for both revenue and Adjusted EBITDA,” said Dan Burton, CEO of Health Catalyst. €œStepping back, bactrim and zithromax we have now reported as a public company for twelve quarters following our IPO in July 2019. As I reflect on this experience, I am extremely proud of the track record we have demonstrated related to our actual quarterly revenue and Adjusted EBITDA performance over this time period relative to the guidance we have provided.

This consistency of performance was something we as a management team set as an objective, several years before going public, and we are pleased to have delivered this level of consistency during our first three years as a public company. Likewise, I want to acknowledge how proud I am bactrim and zithromax of our company for achieving positive Q1 2022 Adjusted EBITDA. At the time of our IPO, almost three years ago, we made a commitment to our investors to reach Adjusted EBITDA breakeven entering the year 2022. Despite a global zithromax and realizing meaningful wage pressure within a tightening labor market, we delivered on this milestone, due to our team members’ hard work and unrelenting commitment to our mission.” Financial Highlights for the Three Months Ended March 31, 2022 Key Financial Metrics Three Months Ended March 31, Year over Year Change 2022 2021 GAAP Financial Data:(in thousands, except percentages, unaudited)Technology revenue$42,230 $33,839 25%Professional services revenue$25,857 $22,007 17%Total revenue$68,087 $55,846 22%Loss from operations$(24,347) $(24,317) —%Net loss$(22,458) $(28,370) 21%Other Non-GAAP Financial Data:(1) Adjusted Technology Gross Profit$29,598 $23,388 27%Adjusted Technology Gross Margin 70% 69% Adjusted Professional Services Gross Profit$7,574 $6,929 9%Adjusted Professional Services Gross Margin 29% 31% Total Adjusted Gross Profit$37,172 $30,317 23%Total Adjusted Gross Margin 55% 54% Adjusted EBITDA$671 $(837) 180% ________________________ (1) These measures are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). See the accompanying "Non-GAAP Financial Measures" section below for more information about these financial measures, including the limitations of bactrim and zithromax such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP.

Financial Outlook Health Catalyst provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure. For the second quarter of 2022, we expect. Total revenue between $68.0 million and $71.0 million, andAdjusted EBITDA between $(1.5) million and $0.5 millionFor the bactrim and zithromax full year of 2022, we expect. Total revenue between $287.8 million and $292.8 million, andAdjusted EBITDA between $(4.0) million and $(2.0) millionWe have not reconciled guidance for Adjusted EBITDA to net loss, the most directly comparable GAAP measure, and have not provided forward-looking guidance for net loss, because there are items that may impact net loss, including stock-based compensation, that are not within our control or cannot be reasonably forecasted. Quarterly Conference Call Details The company will host a conference call to review the results today, Tuesday, May 10, 2022, at 5:00 p.m.

E.T. The conference call can be accessed by dialing 1-877-295-1104 for U.S. Participants, or 1-470-495-9486 for international participants, and referencing participant code 2480316. A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Health Catalyst Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed. Available Information Health Catalyst intends to use its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended.

These forward-looking statements include statements regarding our future growth, and our financial outlook for Q2 and fiscal year 2022. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following. (i) changes in laws and regulations applicable to our business model.

(ii) changes in market or industry conditions, regulatory environment and receptivity to our technology and services. (iii) results of litigation or a security incident. (iv) the loss of one or more key customers or partners. (v) the impact of buy antibiotics on our business and results of operations. And (vi) changes to our abilities to recruit and retain qualified team members.

For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2022 expected to be filed with the SEC on or about May 10, 2022 and the Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 1, 2022. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law. Condensed Consolidated Balance Sheets(in thousands, except share and per share data, unaudited) As ofMarch 31, As ofDecember 31, 2022 2021 (unaudited) Assets Current assets. Cash and cash equivalents$198,428 $193,227 Short-term investments 226,991 251,754 Accounts receivable, net 42,627 48,801 Prepaid expenses and other assets 14,448 14,609 Total current assets 482,494 508,391 Property and equipment, net 24,889 23,316 Intangible assets, net 112,169 104,788 Operating lease right-of-use assets 20,610 21,133 Goodwill 180,336 169,972 Other assets 4,421 4,496 Total assets$824,919 $832,096 Liabilities and stockholders’ equity Current liabilities. Accounts payable$5,865 $4,693 Accrued liabilities 20,226 23,725 Deferred revenue 61,799 56,632 Operating lease liabilities 3,384 3,425 Contingent consideration liabilities 1,379 4,576 Total current liabilities 92,653 93,051 Convertible senior notes, net of current portion 225,397 180,942 Deferred revenue, net of current portion 631 929 Operating lease liabilities, net of current portion 19,699 20,244 Contingent consideration liabilities, net of current portion 5,515 14,719 how much zithromax cost Other liabilities 115 113 Total liabilities 344,010 309,998 Commitments and contingencies Stockholders’ equity.

Preferred stock, $0.001 par value per share. 25,000,000 shares authorized and no shares issued and outstanding as of March 31, 2022 and December 31, 2021 — — Common stock, $0.001 par value per share. 500,000,000 shares authorized as of March 31, 2022 and December 31, 2021. 53,493,683 and 52,622,080 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively 53 53 Additional paid-in capital 1,365,197 1,400,972 Accumulated deficit (884,078) (878,860)Accumulated other comprehensive loss (263) (67)Total stockholders’ equity 480,909 522,098 Total liabilities and stockholders’ equity$824,919 $832,096 Condensed Consolidated Statements of Operations(in thousands, except per share data, unaudited) Three Months EndedMarch 31, 2022 2021 (in thousands)Revenue. Technology$42,230 $33,839 Professional services 25,857 22,007 Total revenue 68,087 55,846 Cost of revenue, excluding depreciation and amortization shown below.

Technology(1)(2) 13,327 10,825 Professional services(1)(2) 20,669 16,513 Total cost of revenue, excluding depreciation and amortization 33,996 27,338 Operating expenses. Sales and marketing(1)(2) 20,818 15,651 Research and development(1)(2) 17,148 14,345 General and administrative(1)(2) 8,823 15,015 Depreciation and amortization 11,649 7,814 Total operating expenses 58,438 52,825 Loss from operations (24,347) (24,317)Interest and other expense, net (1,662) (3,952)Loss before income taxes (26,009) (28,269)Income tax provision (benefit)(2) (3,551) 101 Net loss$(22,458) $(28,370)Net loss per share, basic$(0.42) $(0.65)Net loss per share, diluted$(0.54) $(0.65)Weighted-average shares outstanding used in calculating net loss per share, basic 53,007 43,870 Weighted-average shares outstanding used in calculating net loss per share, diluted 53,215 43,870 Adjusted net loss$(2,967) $(2,753)Adjusted net loss per share, basic and diluted(3)$(0.06) $(0.06)_______________(1) Includes stock-based compensation expense as follows. Three Months EndedMarch 31, 2022 2021 Stock-Based Compensation Expense:(in thousands)Cost of revenue, excluding depreciation and amortization. Technology$589 $374Professional services 2,167 1,435Sales and marketing 7,013 4,818Research and development 3,090 2,257General and administrative 5,261 4,626Total$18,120 $13,510 (2) Includes acquisition-related costs (benefit), net, as follows. Three Months EndedMarch 31, 2022 2021 Acquisition-related costs (benefit), net:(in thousands)Cost of revenue, excluding depreciation and amortization.

Technology$106 $—Professional services 219 —Sales and marketing 397 —Research and development 558 —General and administrative (6,031) 2,156Income tax provision (benefit) (3,600) —Total$(8,351) $2,156 (3) Includes non-GAAP adjustments to net loss. Refer to the "Non-GAAP Financial Measures—Adjusted Net Loss Per Share" section below for further details. Condensed Consolidated Statements of Cash Flows(in thousands, unaudited) Three Months EndedMarch 31, 2022 2021 Cash flows from operating activities Net loss$(22,458) $(28,370)Adjustments to reconcile net loss to net cash used in operating activities. Stock-based compensation expense 18,120 13,510 Depreciation and amortization 11,649 7,814 Non-cash operating lease expense 819 965 Investment discount and premium amortization 398 417 Amortization of debt discount and issuance costs 374 2,870 Provision for expected credit losses 200 300 Deferred tax provision (benefit) (3,598) 2 Payment of acquisition-related contingent consideration (741) — Change in fair value of contingent consideration liabilities (8,424) 2,156 Other (49) (34)Change in operating assets and liabilities. Accounts receivable, net 6,019 2,090 Prepaid expenses and other assets 437 (2,173)Accounts payable, accrued liabilities, and other liabilities (4,812) (5,352)Deferred revenue 4,106 3,745 Operating lease liabilities (882) (1,083)Net cash provided by (used) in operating activities 1,158 (3,143) Cash flows from investing activities Proceeds from the sale and maturity of short-term investments 80,960 53,240 Purchase of short-term investments (56,719) (8,621)Acquisition of business, net of cash acquired (18,509) — Capitalization of internal-use software (3,261) (887)Purchase of intangible assets (463) (480)Purchase of property and equipment (356) (5,882)Proceeds from the sale of property and equipment 4 6 Net cash provided by investing activities 1,656 37,376 Cash flows from financing activities Proceeds from exercise of stock options 1,809 6,488 Proceeds from employee stock purchase plan 1,509 1,349 Payments of acquisition-related consideration (930) (1,391)Net cash provided by financing activities 2,388 6,446 Effect of exchange rate changes on cash and cash equivalents (1) (6)Net increase in cash and cash equivalents 5,201 40,673 Cash and cash equivalents at beginning of period 193,227 91,954 Cash and cash equivalents at end of period$198,428 $132,627 Non-GAAP Financial Measures To supplement our financial information presented in accordance with GAAP, we believe certain non-GAAP measures, including Adjusted Gross Profit, Adjusted Gross Margin, Adjusted EBITDA, Adjusted Net Loss, and Adjusted Net Loss per share, basic and diluted, are useful in evaluating our operating performance.

For example, we exclude stock-based compensation expense because it is non-cash in nature and excluding this expense provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies. We use this non-GAAP financial information to evaluate our ongoing operations, as a component in determining employee bonus compensation, and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance.

A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business. Adjusted Gross Profit and Adjusted Gross Margin Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, adding back stock-based compensation, and acquisition-related costs, net. We define Adjusted Gross Margin as our Adjusted Gross Profit divided by our revenue. We believe Adjusted Gross Profit and Adjusted Gross Margin are useful to investors as they eliminate the impact of certain non-cash expenses and allow a direct comparison of these measures between periods without the impact of non-cash expenses and certain other non-recurring operating expenses.

The following is a reconciliation of revenue, the most directly comparable GAAP financial measure, to Adjusted Gross Profit, for the three months ended March 31, 2022 and 2021. Three Months Ended March 31, 2022 (in thousands, except percentages) Technology Professional Services TotalRevenue$42,230 $25,857 $68,087 Cost of revenue, excluding depreciation and amortization (13,327) (20,669) (33,996)Gross profit, excluding depreciation and amortization 28,903 5,188 34,091 Add. Stock-based compensation 589 2,167 2,756 Acquisition-related costs, net 106 219 325 Adjusted Gross Profit$29,598 $7,574 $37,172 Gross margin, excluding depreciation and amortization 68% 20% 50%Adjusted Gross Margin 70% 29% 55% Three Months Ended March 31, 2021 (in thousands, except percentages) Technology Professional Services TotalRevenue$33,839 $22,007 $55,846 Cost of revenue, excluding depreciation and amortization (10,825) (16,513) (27,338)Gross profit, excluding depreciation and amortization 23,014 5,494 28,508 Add. Stock-based compensation 374 1,435 1,809 Adjusted Gross Profit$23,388 $6,929 $30,317 Gross margin, excluding depreciation and amortization 68% 25% 51%Adjusted Gross Margin 69% 31% 54% Adjusted EBITDA Adjusted EBITDA is a non-GAAP financial measure that we define as net loss adjusted for (i) interest and other expense, net, (ii) income tax (benefit) provision, (iii) depreciation and amortization, (iv) stock-based compensation, and (v) acquisition-related costs, net, including the change in fair value of contingent consideration liabilities. We view acquisition-related expenses when applicable, such as transaction costs and changes in the fair value of contingent consideration liabilities that are directly related to business combinations as costs that are unpredictable, dependent upon factors outside of our control, and are not necessarily reflective of operational performance during a period.

We believe Adjusted EBITDA provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. The following is a reconciliation of our net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA, for the three months ended March 31, 2022 and 2021. Three Months EndedMarch 31, 2022 2021 (in thousands)Net loss$(22,458) $(28,370)Add. Interest and other expense, net 1,662 3,952 Income tax provision (benefit) (3,551) 101 Depreciation and amortization 11,649 7,814 Stock-based compensation 18,120 13,510 Acquisition-related costs, net(1) (4,751) 2,156 Adjusted EBITDA$671 $(837) _______________(1) Acquisition-related costs, net includes third party fees associated with due diligence, deferred retention expenses, post-acquisition restructuring costs incurred as part of business combinations, and changes in fair value of contingent consideration liabilities for potential earn-out payments. For additional details refer to Note 2 in our condensed consolidated financial statements.

Adjusted Net Loss Per Share Adjusted Net Loss is a non-GAAP financial measure that we define as net loss adjusted for (i) stock-based compensation, (ii) amortization of acquired intangibles, (iii) acquisition-related costs, net, including the change in fair value of contingent consideration liabilities and the deferred tax valuation allowance release from the acquisition of KPI Ninja, and (iv) non-cash interest expense related to our convertible senior notes. We believe Adjusted Net Loss provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. Three Months EndedMarch 31, 2022 2021 Numerator:(in thousands, except share and per share amounts)Net loss attributable to common stockholders$(22,458) $(28,370)Add. Stock-based compensation 18,120 13,510 Amortization of acquired intangibles 9,348 7,081 Acquisition-related costs, net(1) (8,351) 2,156 Non-cash interest expense related to convertible senior notes 374 2,870 Adjusted Net Loss$(2,967) $(2,753)Denominator.

HCAT), a leading provider of data and analytics technology and services order zithromax to healthcare organizations, today reported financial results for http://albertgeorgeschram.com/schedule/ the quarter ended March 31, 2022. €œIn the first quarter of 2022, I am pleased to share that we began the year by achieving strong performance across our business, including exceeding the mid-point of our quarterly guidance for both revenue and Adjusted EBITDA,” said Dan Burton, CEO of Health Catalyst. €œStepping back, we have now reported as a public company for twelve quarters following our IPO in July 2019. As I reflect on this experience, I am extremely proud of the track record we have demonstrated related to our actual quarterly revenue and Adjusted order zithromax EBITDA performance over this time period relative to the guidance we have provided.

This consistency of performance was something we as a management team set as an objective, several years before going public, and we are pleased to have delivered this level of consistency during our first three years as a public company. Likewise, I want to acknowledge how proud I am of our company for achieving positive Q1 2022 Adjusted EBITDA. At the time of our IPO, almost three years ago, order zithromax we made a commitment to our investors to reach Adjusted EBITDA breakeven entering the year 2022. Despite a global zithromax and realizing meaningful wage pressure within a tightening labor market, we delivered on this milestone, due to our team members’ hard work and unrelenting commitment to our mission.” Financial Highlights for the Three Months Ended March 31, 2022 Key Financial Metrics Three Months Ended March 31, Year over Year Change 2022 2021 GAAP Financial Data:(in thousands, except percentages, unaudited)Technology revenue$42,230 $33,839 25%Professional services revenue$25,857 $22,007 17%Total revenue$68,087 $55,846 22%Loss from operations$(24,347) $(24,317) —%Net loss$(22,458) $(28,370) 21%Other Non-GAAP Financial Data:(1) Adjusted Technology Gross Profit$29,598 $23,388 27%Adjusted Technology Gross Margin 70% 69% Adjusted Professional Services Gross Profit$7,574 $6,929 9%Adjusted Professional Services Gross Margin 29% 31% Total Adjusted Gross Profit$37,172 $30,317 23%Total Adjusted Gross Margin 55% 54% Adjusted EBITDA$671 $(837) 180% ________________________ (1) These measures are not calculated in accordance with generally accepted accounting principles in the United States (GAAP).

See the accompanying "Non-GAAP Financial Measures" section below for more information about these financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP. Financial Outlook Health Catalyst provides forward-looking guidance on total order zithromax revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure. For the second quarter of 2022, we expect. Total revenue between $68.0 million and $71.0 million, andAdjusted EBITDA between $(1.5) million and $0.5 millionFor the full year of 2022, we expect.

Total revenue between $287.8 million and $292.8 million, andAdjusted EBITDA between $(4.0) million and $(2.0) millionWe have not reconciled guidance for Adjusted EBITDA to net loss, the most directly comparable GAAP measure, and have not provided forward-looking guidance for net loss, because there are items that may impact order zithromax net loss, including stock-based compensation, that are not within our control or cannot be reasonably forecasted. Quarterly Conference Call Details The company will host a conference call to review the results today, Tuesday, May 10, 2022, at 5:00 p.m. E.T. The conference call can be accessed by dialing 1-877-295-1104 for order zithromax U.S.

Participants, or 1-470-495-9486 for international participants, and referencing participant code 2480316. A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days order zithromax. About Health Catalyst Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement.

Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which order zithromax all healthcare decisions are data informed. Available Information Health Catalyst intends to use its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended.

These forward-looking statements include statements order zithromax regarding our future growth, and our financial outlook for Q2 and fiscal year 2022. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Important risks and uncertainties that could order zithromax cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following.

(i) changes in laws and regulations applicable to our business model. (ii) changes in market or industry conditions, regulatory environment and receptivity to our technology and services. (iii) results of order zithromax litigation or a security incident. (iv) the loss of one or more key customers or partners.

(v) the impact of buy antibiotics on our business and results of operations. And (vi) order zithromax changes to our abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2022 expected to be filed with the SEC on or about May 10, 2022 and the Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 1, 2022. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.

Condensed Consolidated order zithromax Balance Sheets(in thousands, except share and per share data, unaudited) As ofMarch 31, As ofDecember 31, 2022 2021 (unaudited) Assets Current assets. Cash and cash equivalents$198,428 $193,227 Short-term investments 226,991 251,754 Accounts receivable, net 42,627 48,801 Prepaid expenses and other assets 14,448 14,609 Total current assets 482,494 508,391 Property and equipment, net 24,889 23,316 Intangible assets, net 112,169 104,788 Operating lease right-of-use assets 20,610 21,133 Goodwill 180,336 169,972 Other assets 4,421 4,496 Total assets$824,919 $832,096 Liabilities and stockholders’ equity Current liabilities. Accounts payable$5,865 $4,693 Accrued liabilities 20,226 23,725 Deferred revenue 61,799 56,632 Operating lease liabilities 3,384 3,425 Contingent consideration liabilities 1,379 4,576 Total current liabilities 92,653 93,051 Convertible senior notes, net of current portion 225,397 180,942 Deferred revenue, net of current portion 631 929 Operating lease liabilities, net of current portion 19,699 20,244 Contingent consideration liabilities, net of current portion 5,515 14,719 Other liabilities 115 113 Total liabilities 344,010 309,998 Commitments and contingencies Stockholders’ equity. Preferred order zithromax stock, $0.001 par value per share.

25,000,000 shares authorized and no shares issued and outstanding as of March 31, 2022 and December 31, 2021 — — Common stock, $0.001 par value per share. 500,000,000 shares authorized as of March 31, 2022 and December 31, 2021. 53,493,683 and 52,622,080 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively 53 53 Additional paid-in capital 1,365,197 1,400,972 Accumulated deficit (884,078) (878,860)Accumulated other comprehensive loss (263) (67)Total stockholders’ equity 480,909 522,098 Total liabilities and stockholders’ equity$824,919 $832,096 Condensed Consolidated Statements of Operations(in thousands, except per order zithromax share data, unaudited) Three Months EndedMarch 31, 2022 2021 (in thousands)Revenue. Technology$42,230 $33,839 Professional services 25,857 22,007 Total revenue 68,087 55,846 Cost of revenue, excluding depreciation and amortization shown below.

Technology(1)(2) 13,327 10,825 Professional services(1)(2) 20,669 16,513 Total cost of revenue, excluding depreciation and amortization 33,996 27,338 Operating expenses. Sales and marketing(1)(2) 20,818 15,651 Research and development(1)(2) 17,148 14,345 General and administrative(1)(2) 8,823 15,015 Depreciation and amortization 11,649 7,814 Total operating expenses 58,438 52,825 Loss from operations (24,347) (24,317)Interest and other expense, net (1,662) (3,952)Loss before income taxes (26,009) (28,269)Income tax provision (benefit)(2) (3,551) 101 Net loss$(22,458) $(28,370)Net loss per share, basic$(0.42) $(0.65)Net loss per share, diluted$(0.54) $(0.65)Weighted-average shares outstanding used in calculating net loss per share, order zithromax basic 53,007 43,870 Weighted-average shares outstanding used in calculating net loss per share, diluted 53,215 43,870 Adjusted net loss$(2,967) $(2,753)Adjusted net loss per share, basic and diluted(3)$(0.06) $(0.06)_______________(1) Includes stock-based compensation expense as follows. Three Months EndedMarch 31, 2022 2021 Stock-Based Compensation Expense:(in thousands)Cost of revenue, excluding depreciation and amortization. Technology$589 $374Professional services 2,167 1,435Sales and marketing 7,013 4,818Research and development 3,090 2,257General and administrative 5,261 4,626Total$18,120 $13,510 (2) Includes acquisition-related costs (benefit), net, as follows.

Three Months EndedMarch 31, 2022 2021 Acquisition-related costs (benefit), net:(in thousands)Cost of revenue, excluding depreciation and order zithromax amortization. Technology$106 $—Professional services 219 —Sales and marketing 397 —Research and development 558 —General and administrative (6,031) 2,156Income tax provision (benefit) (3,600) —Total$(8,351) $2,156 (3) Includes non-GAAP adjustments to net loss. Refer to the "Non-GAAP Financial Measures—Adjusted Net Loss Per Share" section below for further details. Condensed Consolidated Statements of Cash Flows(in thousands, unaudited) Three Months EndedMarch 31, 2022 2021 Cash flows from operating activities Net order zithromax loss$(22,458) $(28,370)Adjustments to reconcile net loss to net cash used in operating activities.

Stock-based compensation expense 18,120 13,510 Depreciation and amortization 11,649 7,814 Non-cash operating lease expense 819 965 Investment discount and premium amortization 398 417 Amortization of debt discount and issuance costs 374 2,870 Provision for expected credit losses 200 300 Deferred tax provision (benefit) (3,598) 2 Payment of acquisition-related contingent consideration (741) — Change in fair value of contingent consideration liabilities (8,424) 2,156 Other (49) (34)Change in operating assets and liabilities. Accounts receivable, net 6,019 2,090 Prepaid expenses and other assets 437 (2,173)Accounts payable, accrued liabilities, and other liabilities (4,812) (5,352)Deferred revenue 4,106 3,745 Operating lease liabilities (882) (1,083)Net cash provided by (used) in operating activities 1,158 (3,143) Cash flows from investing activities Proceeds from the sale and maturity of short-term investments 80,960 53,240 Purchase of short-term investments (56,719) (8,621)Acquisition of business, net of cash acquired (18,509) — Capitalization of internal-use software (3,261) (887)Purchase of intangible assets (463) (480)Purchase of property and equipment (356) (5,882)Proceeds from the sale of property and equipment 4 6 Net cash provided by investing activities 1,656 37,376 Cash flows from financing activities Proceeds from exercise of stock options 1,809 6,488 Proceeds from employee stock purchase plan 1,509 1,349 Payments of acquisition-related consideration (930) (1,391)Net cash provided by financing activities 2,388 6,446 Effect of exchange rate changes on cash and cash equivalents (1) (6)Net increase in cash and cash equivalents 5,201 40,673 Cash and cash equivalents at beginning of period 193,227 91,954 Cash and cash equivalents at end of period$198,428 $132,627 Non-GAAP Financial Measures To supplement our financial information presented in accordance with GAAP, we believe certain non-GAAP measures, including Adjusted Gross Profit, Adjusted Gross Margin, Adjusted EBITDA, Adjusted Net Loss, and Adjusted Net Loss per share, basic and diluted, are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense because it is non-cash in nature and excluding this expense provides meaningful supplemental order zithromax information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies. We use this non-GAAP financial information to evaluate our ongoing operations, as a component in determining employee bonus compensation, and for internal planning and forecasting purposes.

We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered order zithromax in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP.

Investors are encouraged to review the related GAAP financial measures and the reconciliation of these order zithromax non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business. Adjusted Gross Profit and Adjusted Gross Margin Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, adding back stock-based compensation, and acquisition-related costs, net. We define Adjusted Gross Margin as our Adjusted Gross Profit divided by our revenue. We believe Adjusted Gross Profit and Adjusted Gross Margin are useful to investors as they eliminate the impact of certain non-cash expenses and allow a direct comparison of these measures between periods without the impact of non-cash expenses and certain other non-recurring operating expenses.

The following is a reconciliation of revenue, the most directly comparable GAAP financial measure, to Adjusted Gross Profit, for the three months ended March 31, 2022 and 2021. Three Months Ended March 31, 2022 (in thousands, except percentages) Technology Professional Services TotalRevenue$42,230 $25,857 $68,087 Cost of revenue, excluding depreciation and amortization (13,327) (20,669) (33,996)Gross profit, excluding depreciation and amortization 28,903 5,188 34,091 Add. Stock-based compensation 589 2,167 2,756 Acquisition-related costs, net 106 219 325 Adjusted Gross Profit$29,598 $7,574 $37,172 Gross margin, excluding depreciation and amortization 68% 20% 50%Adjusted Gross Margin 70% 29% 55% Three Months Ended March 31, 2021 (in thousands, except percentages) Technology Professional Services TotalRevenue$33,839 $22,007 $55,846 Cost of revenue, excluding depreciation and amortization (10,825) (16,513) (27,338)Gross profit, excluding depreciation and amortization 23,014 5,494 28,508 Add. Stock-based compensation 374 1,435 1,809 Adjusted Gross Profit$23,388 $6,929 $30,317 Gross margin, excluding depreciation and amortization 68% 25% 51%Adjusted Gross Margin 69% 31% 54% Adjusted EBITDA Adjusted EBITDA is a non-GAAP financial measure that we define as net loss adjusted for (i) interest and other expense, net, (ii) income tax (benefit) provision, (iii) depreciation and amortization, (iv) stock-based compensation, and (v) acquisition-related costs, net, including the change in fair value of contingent consideration liabilities.

We view acquisition-related expenses when applicable, such as transaction costs and changes in the fair value of contingent consideration liabilities that are directly related to business combinations as costs that are unpredictable, dependent upon factors outside of our control, and are not necessarily reflective of operational performance during a period. We believe Adjusted EBITDA provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. The following is a reconciliation of our net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA, for the three months ended March 31, 2022 and 2021. Three Months EndedMarch 31, 2022 2021 (in thousands)Net loss$(22,458) $(28,370)Add.

Interest and other expense, net 1,662 3,952 Income tax provision (benefit) (3,551) 101 Depreciation and amortization 11,649 7,814 Stock-based compensation 18,120 13,510 Acquisition-related costs, net(1) (4,751) 2,156 Adjusted EBITDA$671 $(837) _______________(1) Acquisition-related costs, net includes third party fees associated with due diligence, deferred retention expenses, post-acquisition restructuring costs incurred as part of business combinations, and changes in fair value of contingent consideration liabilities for potential earn-out payments. For additional details refer to Note 2 in our condensed consolidated financial statements. Adjusted Net Loss Per Share Adjusted Net Loss is a non-GAAP financial measure that we define as net loss adjusted for (i) stock-based compensation, (ii) amortization of acquired intangibles, (iii) acquisition-related costs, net, including the change in fair value of contingent consideration liabilities and the deferred tax valuation allowance release from the acquisition of KPI Ninja, and (iv) non-cash interest expense related to our convertible senior notes. We believe Adjusted Net Loss provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

Three Months EndedMarch 31, 2022 2021 Numerator:(in thousands, except share and per share amounts)Net loss attributable to common stockholders$(22,458) $(28,370)Add. Stock-based compensation 18,120 13,510 Amortization of acquired intangibles 9,348 7,081 Acquisition-related costs, net(1) (8,351) 2,156 Non-cash interest expense related to convertible senior notes 374 2,870 Adjusted Net Loss$(2,967) $(2,753)Denominator. Weighted-average number of shares used in calculating net loss, basic 53,006,704 43,870,288 Weighted-average number of shares used in calculating net loss, diluted 53,215,030 43,870,288 Adjusted net loss per share, basic and diluted$(0.06) $(0.06)______________(1) Acquisition-related costs, net includes third party fees associated with due diligence, deferred retention expenses, post-acquisition restructuring costs incurred as part of business combinations, changes in fair value of contingent consideration liabilities for potential earn-out payments, and the deferred tax valuation allowance release from the acquisition of KPI Ninja.